The food allergy medicine spinout from UChicago has been backed by the institution itself in a $3.5m seed round.

Taiho Pharmaceutical has invested in a series A round for the small-molecule therapy developer that now totals $21.6m.

The brain monitor developer has now raised a total of $42m from backers that include clinical development services provider TigerMed.

The pharmaceutical company, which has overseen a venture capital unit since 2004, will form the fund as it cuts internal neuroscience research.

The Sarnoff spinoff will use the financing to commercialise its diabetes management and glucose measuring technology in the US.

Qualcomm-backed Practice Fusion has agreed to an acquisition by Allscripts, having once been touted for an IPO that would have valued it at $1.5bn.

The Cambridge genomics spinout has secured $5.4m in additional series A funding from drug maker Taiho Pharmaceutical.

Agent Capital, formed by Ex-Baxalta Ventures managing partner Geeta Vemuri, has raised $52m of a planned $150m for its first fund.

GE Ventures, Kaiser Permanente Ventures and existing backer Illumina Ventures have helped Genome Medical take its total funding to $23m

KBP Biosciences, which is developing drugs for disease areas of unmet need, raised the series A funds from investors including Cash Capital.